Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis

International Journal of Cancer

Volumn 132, Issue 1, 2013, Pages 109-115

  Setsu, Nokitaka ^a   Kohashi, Kenichi ^a   Endo, Makoto ^a   Yamamoto, Hidetaka ^a   Tamiya, Sadafumi ^a   Takahashi, Yusuke ^a   Yamada, Yuichi ^a   Ishii, Takeaki ^a   Matsuda, Shuichi ^a   Yokoyama, Ryohei ^b   Iwamoto, Yukihide ^a   Oda, Yoshinao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

prognosis; signal transducer and activator of transcription 3 (STAT3); soft tissue leiomyosarcoma; suppressor of cytokine signaling 3 (SOCS3)

Indexed keywords

FORMALDEHYDE; PARAFFIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ARTICLE; BENIGN TUMOR; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FROZEN SECTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MUSCLE TISSUE; MUSCLE TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOFT TISSUE LEIOMYOSARCOMA; SOFT TISSUE TUMOR; TUMOR GROWTH; WESTERN BLOTTING;

FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROGNOSIS; PROTEIN INHIBITORS OF ACTIVATED STAT; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84868192377     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27655     Document Type: Article

References (32)

1. Oda Y, Tamiya S, Oshiro Y, et al. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int 2002; 52: 595-606.
2. Khoury JD, Medeiros LJ, Rassidakis GZ, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 2003; 9: 3692-9.
3. Kusaba T, Nakayama T, Yamazumi K, et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005; 58: 833-8.
4. Rosen DG, Mercado-Uribe I, Yang G, et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006; 107: 2730-40.
5. Chapman RS, Lourenco PC, Tonner E, et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 1999; 13: 2604-16.
6. Dolled-Filhart M, Camp RL, Kowalski DP, et al. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003; 9: 594-600.
7. Hsiao JR, Jin YT, Tsai ST, et al. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 2003; 89: 344-9.
8. Lai R, Navid F, Rodriguez-Galindo C, et al. STAT3 is activated in a subset of the ewing sarcoma family of tumours. J Pathol 2006; 208: 624-32.
9. Choi CH, Song SY, Kang H, et al. Prognostic significance of p-STAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. J Obstet Gynaecol Res 2010; 36: 304-10.
10. Pectasides E, Egloff AM, Sasaki C, et al. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res 2010; 16: 2427-34.
11. Setsu N, Yamamoto H, Kohashi K, et al. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer 2012; 118: 1637-48.
12. Oda Y, Miyajima K, Kawaguchi K, et al. Pleomorphic leiomyosarcoma: clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma. Am J Surg Pathol 2001; 25: 1030-8.
13. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC cancer staging manual, 7th edn. St. Louis: Springer, 2010. 293-5.
14. Dobashi Y, Suzuki S, Sugawara H, et al. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum Pathol 2007; 38: 914-25.
15. Ying M, Li D, Yang L, et al. Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J Cancer Res Clin Oncol 2010; 136: 1617-26.
16. Darnell JE, Jr,. STATs and gene regulation. Science 1997; 277: 1630-5.
17. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999; 98: 295-303.
18. Rahaman SO, Harbor PC, Chernova O, et al. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002; 21: 8404-13.
19. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000-8.
20. Chen CL, Loy A, Cen L, et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. Biomed Chromatogr Cancer 2007; 7: 111.
21. Lin N, Uchi H, Moroi Y, et al. Significance of the expression of phosphorylated signal transducer and activator of transcription-3, -akt, and -cyclin D1 in angiosarcoma. J Dermatol Sci 2007; 48: 64-6.
22. Dobashi Y, Suzuki S, Sato E, et al. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol 2009; 22: 1328-40.
23. Nicholson SE, De Souza D, Fabri LJ, et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 2000; 97: 6493-8.
24. Cooney RN,. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock 2002; 17: 83-90.
25. Krishnadasan R, Bifulco C, Kim J, et al. Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma. Br J Haematol 2006; 135: 72-5.
26. Puhr M, Santer FR, Neuwirt H, et al. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res 2009; 69: 7375-84.
27. Ruan M, Pederson L, Bradley EW, et al. Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis. Endocrinology 2010; 151: 1713-22.
28. Tomita S, Ishibashi K, Hashimoto K, et al. Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-alpha. Cancer Sci 2011; 102: 57-63.
29. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278: 1803-5.
30. Bousquet C, Susini C, Melmed S,. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest 1999; 104: 1277-85.
31. Kim DJ, Tremblay ML, Digiovanni J,. Protein tyrosine phosphatases, TC-PTP, SHP1, and SHP2, cooperate in rapid dephosphorylation of Stat3 in keratinocytes following UVB irradiation. PLoS One 2010; 5: e10290.
32. Chung J, Uchida E, Grammer TC, et al. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997; 17: 6508-16.